Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 31, Issue 6, Pages 952-961Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-011-9588-5
Keywords
Primary immunodeficiency; subcutaneous immunoglobulin; local tolerability; serum IgG levels
Categories
Funding
- CSL Behring AG, Berne, Switzerland
- Hospital St. Georg GmbH Leipzig, Academic Teaching Hospital of the University of Leipzig, Leipzig, Germany
- Unidad de Inmunolog a Clinica, Hospital General Universitario Gregorio Maranon, Departamento Microbiolog a I e Inmunologia, Universidad Complutense de Madrid, Madrid, Spain
- CSL Behring, Baxter
- Baxter
- CSL Behring
- Fondo de Investigacion Instituto Carlos III
- GlaxoSmithKline
Ask authors/readers for more resources
Treatment of primary immunodeficiency (PI) is typically initiated with intravenous immunoglobulin (IVIG) loading and then continued with IVIG or subcutaneous IgG (SCIG). This prospective, open-label, multicenter, 6-month study evaluated a new regimen of initiating IgG therapy with SCIG in 18 previously untreated patients. In the loading phase, SCIG 100 mg/kg was administered for five consecutive days (total loading dose 500 mg/kg). During the maintenance phase, patients self-infused SCIG 100 mg/kg/week at home. The primary efficacy endpoint of IgG levels a parts per thousand yen5 g/L on day 12 was achieved in 17 patients (94.4%; 95% CI 0.727, 0.999). The rate of infections was 3.95 episodes/patient/year. Improvement was found in many subscales of the health-related quality of life questionnaires. SCIG treatment was well tolerated, with no related serious adverse events (AEs). Nine (50%) patients experienced related AEs, including local reactions (rate 0.105 events/infusion). The results suggest that therapy of newly diagnosed patients with PI can be initiated directly with SCIG.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available